Concomitant administration of uracil-tegafur and leucovorin during adjuvant radiotherapy for locally advanced rectal cancer


Atasoy B. M., Abacioglu U., Dane F., Ozgen Z., Yumuk P. F., Ozden S., ...Daha Fazla

Journal of B.U.ON., cilt.12, sa.2, ss.203-208, 2007 (Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 12 Sayı: 2
  • Basım Tarihi: 2007
  • Dergi Adı: Journal of B.U.ON.
  • Derginin Tarandığı İndeksler: Scopus
  • Sayfa Sayıları: ss.203-208
  • Anahtar Kelimeler: Concomitant chemoradiotherapy, Oral fuoropyimidine, Rectal cancer, Survival, Toxicity, UFT
  • Marmara Üniversitesi Adresli: Evet

Özet

Purpose: We report the feasibility and toxicity profile, and the impact on local control, disease-free survival and overall survival rates of our study which consisted of postoperative concurrent chemoradiotherapy, followed by adjuvant chemotherapy using uracil-tegafur (UFT)/leukovorin (LV) in locally advanced rectal cancer patients. Patients and methods: Thirty-one patients operated for rectal adenocarcinoma (pT3/4 or N+) were enrolled onto the study. Twenty-three patients were males and 8 females with median age 62 years (range 21-85). Radiotherapy (RT) to the pelvis with conformal technique and individual blocks was delivered within 8 weeks following surgery. Total RT dose was 50.4 Gy and was given in a conventional single fraction of 1.8 Gyper day. Chemotherapy was administered concomitantly and consisted of UFT(300mg/m2/day) and LV (30mg/day) during RT-days. Following chemoradiotherapy, chemotherapy alone was administered for 4 cycles in the same dose for 28 days every 35 days. Results: No lethal toxicity occurred. All patients completed the scheduled RT Concurrent chemotherapy continued in 22 (70.9%) patients until the end of RT. Seventeen (54.8%) patients completed the whole concurrent chemoradiotherapy and adjuvant chemotherapy as planned, No grade 3-4 stomatitis/mucositis or haematological toxicities were observed during the whole treatment period. During concomitant therapy grade 1-2 toxicities were: nausea/vomiting 60%, dyspepsia/gastric pain 39%, diarrhea 39% and dysuria 10%, whereas grade 3 nausea and diarrhea occurred in 6% and 19%, respectively. Median follow-up was 22 months. Two-year local control, disease-free survival and overall survival rates were 96.3%, 72.3% and 83.2%, respectively. Conclusion: The acute toxicity profile of UFT/LV, local control, disease-free survival and overall survival in the concurrent chemoradiotherapy setting for operated, locally advanced rectal cancer seem comparable with the standard 5-fluorouracil (5-FU)-based therapies. © 2007 Zerbinis Medical Publications.